Risk of Serious Infection

Research output: Contribution to journalArticle

Abstract

Anti-TNF therapy is effective for inducing and maintaining remission in both pediatric Crohn's disease and ulcerative colitis patients; however, adverse effects, such as serious infection and lymphoma, are of concern. A recent study has indicated that anti-TNFα therapy in patients aged ≥50 years is associated with significantly increased rates of serious infections; therefore, physicians should pay careful attention to detect the development of infections in elderly patients treated with this therapy. Patients with inflammatory bowel disease (IBD) should be considered for the five following vaccines: the varicella zoster, human papillomavirus, influenza, hepatitis B, and pneumococcal vaccines. Because IBD patients often fail to recognize whether they have previously had a vaccine-preventive illness, such as varicella zoster virus infection, antibodies for varicella zoster virus should be measured as early as possible after diagnosis of IBD, and vaccination might be considered for patients who do not have antibodies before anti-TNFα agents are used.

Original languageEnglish
Pages (from-to)147-151
Number of pages5
JournalFrontiers of Gastrointestinal Research
Volume34
DOIs
Publication statusPublished - 2015

Fingerprint

Infection
Inflammatory Bowel Diseases
Human Herpesvirus 3
Herpes Zoster Vaccine
Chickenpox Vaccine
Hepatitis B Vaccines
Pneumococcal Vaccines
Virus Diseases
Ulcerative Colitis
Human Influenza
Anti-Idiotypic Antibodies
Lymphoma
Vaccination
Therapeutics
Vaccines
Physicians
Antibodies

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Risk of Serious Infection. / Naganuma, Makoto.

In: Frontiers of Gastrointestinal Research, Vol. 34, 2015, p. 147-151.

Research output: Contribution to journalArticle

@article{dfe737315d1946f58c649b2274624cea,
title = "Risk of Serious Infection",
abstract = "Anti-TNF therapy is effective for inducing and maintaining remission in both pediatric Crohn's disease and ulcerative colitis patients; however, adverse effects, such as serious infection and lymphoma, are of concern. A recent study has indicated that anti-TNFα therapy in patients aged ≥50 years is associated with significantly increased rates of serious infections; therefore, physicians should pay careful attention to detect the development of infections in elderly patients treated with this therapy. Patients with inflammatory bowel disease (IBD) should be considered for the five following vaccines: the varicella zoster, human papillomavirus, influenza, hepatitis B, and pneumococcal vaccines. Because IBD patients often fail to recognize whether they have previously had a vaccine-preventive illness, such as varicella zoster virus infection, antibodies for varicella zoster virus should be measured as early as possible after diagnosis of IBD, and vaccination might be considered for patients who do not have antibodies before anti-TNFα agents are used.",
author = "Makoto Naganuma",
year = "2015",
doi = "10.1159/000381595",
language = "English",
volume = "34",
pages = "147--151",
journal = "Frontiers of Gastrointestinal Research",
issn = "0302-0665",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Risk of Serious Infection

AU - Naganuma, Makoto

PY - 2015

Y1 - 2015

N2 - Anti-TNF therapy is effective for inducing and maintaining remission in both pediatric Crohn's disease and ulcerative colitis patients; however, adverse effects, such as serious infection and lymphoma, are of concern. A recent study has indicated that anti-TNFα therapy in patients aged ≥50 years is associated with significantly increased rates of serious infections; therefore, physicians should pay careful attention to detect the development of infections in elderly patients treated with this therapy. Patients with inflammatory bowel disease (IBD) should be considered for the five following vaccines: the varicella zoster, human papillomavirus, influenza, hepatitis B, and pneumococcal vaccines. Because IBD patients often fail to recognize whether they have previously had a vaccine-preventive illness, such as varicella zoster virus infection, antibodies for varicella zoster virus should be measured as early as possible after diagnosis of IBD, and vaccination might be considered for patients who do not have antibodies before anti-TNFα agents are used.

AB - Anti-TNF therapy is effective for inducing and maintaining remission in both pediatric Crohn's disease and ulcerative colitis patients; however, adverse effects, such as serious infection and lymphoma, are of concern. A recent study has indicated that anti-TNFα therapy in patients aged ≥50 years is associated with significantly increased rates of serious infections; therefore, physicians should pay careful attention to detect the development of infections in elderly patients treated with this therapy. Patients with inflammatory bowel disease (IBD) should be considered for the five following vaccines: the varicella zoster, human papillomavirus, influenza, hepatitis B, and pneumococcal vaccines. Because IBD patients often fail to recognize whether they have previously had a vaccine-preventive illness, such as varicella zoster virus infection, antibodies for varicella zoster virus should be measured as early as possible after diagnosis of IBD, and vaccination might be considered for patients who do not have antibodies before anti-TNFα agents are used.

UR - http://www.scopus.com/inward/record.url?scp=84937937449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937937449&partnerID=8YFLogxK

U2 - 10.1159/000381595

DO - 10.1159/000381595

M3 - Article

AN - SCOPUS:84937937449

VL - 34

SP - 147

EP - 151

JO - Frontiers of Gastrointestinal Research

JF - Frontiers of Gastrointestinal Research

SN - 0302-0665

ER -